| Drug Name |
Lincomycin hydrochloride |
| Drug ID |
BADD_D01293 |
| Description |
Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium _Streptomyces lincolnensis_ in Lincoln, Nebraska.[A190621] Clinical use of lincomycin has largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.[A190657, A190621]
Lincomycin was approved by the FDA on December 29, 1964.[L33214] |
| Indications and Usage |
Lincomycin is indicated for the treatment of serious bacterial infections by susceptible strains of streptococci, pneumococci, and staphylococci in patients who are allergic to penicillins or for situations in which a penicillin is deemed inappropriate. As with all antibacterial agents, lincomycin should only be used to treat infections proven or strongly suspected to be caused by susceptible bacteria.[L33214] |
| Marketing Status |
approved; vet_approved |
| ATC Code |
J01FF02 |
| DrugBank ID |
DB01627
|
| KEGG ID |
D02346; D00223
|
| MeSH ID |
D008034
|
| PubChem ID |
64710
|
| TTD Drug ID |
D0Q0EX
|
| NDC Product Code |
39822-0353; 51927-3177; 50090-4533; 43781-2301; 52584-353; 0404-9901; 42881-0001; 39822-0350; 68083-478; 0009-5168; 0009-0555; 20076-0404; 68083-479; 25021-193 |
| UNII |
M6T05Z2B68
|
| Synonyms |
Lincomycin | Lincomycin A | Lincolnensin | Lincomycin Hydrochloride | Lincomycin Monohydrochloride | Lincomycin, (L-threo)-Isomer | Epilincomycin | Lincomycin Monohydrochloride, (L-threo)-Isomer | Lincomycin Monohydrochloride, Hemihydrate | Hemihydrate Lincomycin Monohydrochloride | Lincomycin, (2S-cis)-Isomer | Lincocin | Lincomycin Monohydrochloride, (2S-cis)-Isomer |
